Latest Insider Transactions at Evolus, Inc. (EOLS)
This section provides a real-time view of insider transactions for Evolus, Inc. (EOLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Evolus, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Evolus, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2022
|
Lauren P Silvernail Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,571
+19.58%
|
-
|
|
Jan 24
2022
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
214,286
+26.6%
|
-
|
|
Jan 05
2022
|
Brady Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,508
+50.0%
|
-
|
|
Sep 02
2021
|
Alphaeon 1 LLC |
SELL
Open market or private sale
|
Direct |
2,597,475
-29.99%
|
$23,377,275
$9.5 P/Share
|
|
Aug 27
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
51,000
+0.68%
|
$510,000
$10.93 P/Share
|
|
Aug 26
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
66,000
+0.88%
|
$726,000
$11.02 P/Share
|
|
Aug 25
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
44,000
+0.6%
|
$484,000
$11.12 P/Share
|
|
Aug 24
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
72,219
+0.98%
|
$794,409
$11.17 P/Share
|
|
Aug 23
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
69,781
+0.96%
|
$767,591
$11.03 P/Share
|
|
Aug 23
2021
|
Vikram Malik Director |
SELL
Open market or private sale
|
Indirect |
26,077
-2.23%
|
$286,847
$11.0 P/Share
|
|
Aug 20
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
48,000
+0.67%
|
$480,000
$10.56 P/Share
|
|
Aug 20
2021
|
Vikram Malik Director |
SELL
Open market or private sale
|
Indirect |
49,878
-4.09%
|
$498,780
$10.61 P/Share
|
|
Aug 19
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
55,000
+0.77%
|
$550,000
$10.51 P/Share
|
|
Aug 19
2021
|
Vikram Malik Director |
SELL
Open market or private sale
|
Indirect |
11,962
-0.97%
|
$119,620
$10.5 P/Share
|
|
Aug 18
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
45,000
+0.63%
|
$450,000
$10.54 P/Share
|
|
Aug 18
2021
|
Vikram Malik Director |
SELL
Open market or private sale
|
Indirect |
25,000
-1.99%
|
$250,000
$10.44 P/Share
|
|
Aug 17
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
70,000
+0.99%
|
$700,000
$10.69 P/Share
|
|
Aug 17
2021
|
Vikram Malik Director |
SELL
Open market or private sale
|
Indirect |
42,083
-3.24%
|
$420,830
$10.06 P/Share
|
|
Aug 16
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
65,000
+0.93%
|
$715,000
$11.34 P/Share
|
|
Aug 16
2021
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
47,737
-11.24%
|
$525,107
$11.35 P/Share
|
|
Aug 13
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Indirect |
14,043
+0.19%
|
$154,473
$11.11 P/Share
|
|
Aug 13
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
49,714
+0.72%
|
$497,140
$10.98 P/Share
|
|
Aug 13
2021
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
22,708
-5.07%
|
$227,080
$10.66 P/Share
|
|
Aug 12
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Indirect |
23,000
+0.31%
|
$230,000
$10.99 P/Share
|
|
Aug 12
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
39,126
+0.57%
|
$391,260
$10.93 P/Share
|
|
Aug 11
2021
|
Medytox Inc. |
BUY
Open market or private purchase
|
Direct |
26,160
+0.38%
|
$261,600
$10.77 P/Share
|
|
Aug 10
2021
|
David Moatazedi Director |
BUY
Open market or private sale
|
Direct |
41,763
+7.29%
|
$459,393
$11.18 P/Share
|
|
Aug 10
2021
|
Crystal Muilenburg Chief Marketing Officer |
BUY
Open market or private sale
|
Direct |
5,362
+5.02%
|
$58,982
$11.18 P/Share
|
|
Aug 10
2021
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
14,293
-6.38%
|
$157,223
$11.18 P/Share
|
|
Aug 10
2021
|
Lauren P Silvernail Officer |
BUY
Open market or private sale
|
Direct |
14,293
+6.83%
|
$157,223
$11.18 P/Share
|
|
Mar 26
2021
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
48,853
+9.08%
|
-
|
|
Mar 26
2021
|
Vikram Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,011
+25.11%
|
-
|
|
Feb 05
2021
|
Simone Blank Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,313
+50.0%
|
-
|
|
Feb 05
2021
|
Karah Herdman Parschauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,313
+50.0%
|
-
|
|
Feb 05
2021
|
Peter C Farrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,313
+50.0%
|
-
|
|
Feb 05
2021
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,313
+44.27%
|
-
|
|
Feb 05
2021
|
Robert Hayman Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,313
+50.0%
|
-
|
|
Feb 05
2021
|
Vikram Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,313
+35.1%
|
-
|
|
Jan 27
2021
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
266,667
+37.71%
|
-
|
|
Jan 27
2021
|
Rui Avelar Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+28.65%
|
-
|
|
Jan 27
2021
|
Lauren P Silvernail Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+33.25%
|
-
|
|
Jan 27
2021
|
Michael M. Jafar Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+16.99%
|
-
|
|
Jan 25
2021
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
8,310
-4.56%
|
$58,170
$7.46 P/Share
|
|
Jan 25
2021
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
2,699
-1.97%
|
$18,893
$7.46 P/Share
|
|
Jan 25
2021
|
Michael M. Jafar Officer |
SELL
Open market or private sale
|
Direct |
2,699
-1.52%
|
$18,893
$7.46 P/Share
|
|
Jan 25
2021
|
Lauren P Silvernail Officer |
SELL
Open market or private sale
|
Direct |
2,699
-2.89%
|
$18,893
$7.46 P/Share
|
|
Oct 28
2020
|
Michael M. Jafar Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,550
+21.47%
|
-
|